Professors Fulvio D’Acquisto and Yehuda Shoenfeld Have Joined the Brainimmune Editorial Board

BrainImmune Cover
NEWS RELEASE

BrainImmune – We are pleased to announce that professors Fulvio D’Acquisto and Yehuda Shoenfeld have joined the BrainImmune Editorial Board.

We are confident that this will help us to broaden our horizons, expand the BrainImmune project, and build new sections on immunology or immunopharmacology and autoimmunity.

Professor Fulvio D'AcquistoProfessor Fulvio D’Acquisto is the Director of the Health Science Centre, Department of Life Science, University of Roehampton, and Honorary Professor of Immunopharmacology, Queen Mary University of London, the UK.

Fulvio has always been fascinated by the idea that the body has its own arsenal of weapons to tame and control an unhealthy immune response.

With a PhD degree from the University of Naples, Italy, and training in molecular immunology at Yale University, Fulvio has focused his research on the design of novel immunomodulatory drugs for different types of inflammatory and autoimmune conditions. This included the discovery of VJ-4B6: a new neutralizing antibody against Annexin-A1, with beneficial therapeutic effects in mouse models of autoimmune diseases. This antibody has been already humanised and has now predicted to enter clinical trials later this year or in 2022.

Following the success of what was done for Annexin-A1, Fulvio and his team have generated neutralizing anti-Imood antibodies that have shown anxiolytic effects in experimental mice. The development of these antibodies could be a potential turning page in the treatment of Obsessive Compulsive Disorders (OCD) as this would be the first example of biological therapy for the treatment of OCD and related disorders.Affective Immunity

Fulvio’s major research focus is also the link between emotions, immunity, and inflammation. He has ‘christened’ this area of research Affective Immunology. Affective immunology is a framework of research based on two fundamental assumptions. The first assumption is based on a large body of both clinical and experimental evidence showing an increased incidence of emotional disorders in patients suffering from immune diseases. The second assumption is based on new and emerging ideas that both the emotional and immune systems are highly “plastic”.

Few selected publications:

PDK1 Nucleates T Cell Receptor-Induced Signaling Complex for NF-κB Activation;
Annexin A1 and glucocorticoids as effectors of the resolution of inflammation;
CD4⁺ but not CD8⁺ T cells revert the impaired emotional behavior of immunocompromised RAG-1-deficient mice;
Affective immunology: where emotions and the immune response converge;
Immuno-moodulin: a new anxiogenic factor produced by Annexin-A1 transgenic autoimmune-prone T cells. Brain Behaviour and Immunity;
Impact of Enriched Environment on Murine T Cell Differentiation;

Professor Yehuda_ShoenfeldProfessor Yehuda Shoenfeld, MD., FRCP, MaACR, is the founder and headed of the Zabludowicz Center for Autoimmune Diseases, at the Sheba Medical Center, which is affiliated to the Sackler Faculty of Medicine in Tel-Aviv University in Israel.

Yehuda’s clinical and scientific work focus on autoimmune and rheumatic diseases, including the effect of autoimmune diseases on the brain, and/or the autoimmune diseases of the brain; the effects of autoantibodies on behavior and depression, etc.

He  has published more than 2150 papers, with over 75000 citations, in journals such as The New England Journal of Medicine, Nature, The Lancet, Proceedings of the National Academy of Sciences of the United States of America, The Journal of Clinical Investigation, The Journal of Immunology, Blood, FASEB, The Journal of Experimental Medicine, Circulation, etc.

He has written more than 350 chapters in books and has authored and edited 25 books, some of which have become cornerstones in science and clinical practice, such as The Mosaic of Autoimmunity and Infection and Autoimmunity, as well as the textbooks Autoantibodies, Vaccines and Autoimmunity, and Diagnostic Criteria in Autoimmune Diseases, all of which were published by Elsevier and sold by the thousands.

Professor Shoenfeld is the founder and the editor of the IMAJ (Israel Medical Association Journal), the representative journal of science and medicine in the English language in Israel; he is the founder and Editor-in-chief of Autoimmunity Reviews (Elsevier); Co-Editor of Journal of Autoimmunity (Elsevier). For the past twenty years Yehuda is the Editor of “Harefuah” – The Israeli Medical Association’s Journal in Hebrew.

Professor Shoenfeld earned Honorary FRCP of the Royal College of Physicians, London, UK, in 2003. He received the EULAR prize in 2005 in Vienna, Austria, for “The infectious etiology of antiphospholipid syndrome.” In UC Davis, USA, Professor Shoenfeld received the Nelson’s Prize for Humanity and Science for 2008. He was also awarded a Life Contribution Prize in Internal Medicine in Israel, in 2012 as well as the ACR Master Award in 2013.

Yehuda is the founder and the driving force of Autoimmunity Network – a dynamic community of more than 4000 physicians, immunologists, rheumatologists & researchers who share the common goal of exchanging knowledge about autoimmune diseases.

Few recent publications:

Neurological Dysfunction Associated with Antiphospholipid Syndrome: Histopathological Brain Findings of Thrombotic Changes in a Mouse Model;
MMP-2, VCAM-1 and NCAM-1 expression in the brain of rats with experimental autoimmune encephalomyelitis as a trigger mechanism for synaptic plasticity and pathology;
Induction of autoimmune depression in mice by anti–ribosomal P antibodies via the limbic system
Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice;
Antibody- specific behavioral effects: Intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice;
Dysregulation of G protein-coupled receptors of the autonomic nervous system, adrenergic and muscarinic acetylcholine receptors, in patients with autoimmune dysautonomic-related disorders